



Daniel M. Silver

Partner

T. 302-984-6331

F. 302-691-1260

dsilver@mccarter.com

McCarter & English, LLP

Renaissance Centre

405 N. King Street, 8th Floor

Wilmington, DE 19801-3717

www.mccarter.com

March 2, 2020

VIA CM/ECF & HAND DELIVERY

The Honorable Colm F. Connolly
United States District Court for the District of Delaware
J. Caleb Boggs Federal Building
844 N. King Street
Unit 31, Room 4124
Wilmington, Delaware 19801-3555

Re: ***Genentech, Inc. v. Amgen Inc.***,
C.A. No. 17-1407-CFC (D. Del.) (consolidated)

Dear Judge Connolly:

I write on behalf of Plaintiffs in the above-referenced action regarding Amgen's letter submitted in advance of the March 5, 2020 status conference. (D.I. 641). Amgen's status conference letter identifies no case management issues that require decision by the Court. Instead, Amgen argues the merits of two of the pending infringement claims. It presumably comes as no surprise to the Court that Genentech sees the merits differently. We will address Amgen's non-infringement arguments at the appropriate time.

Respectfully submitted,

/s/ Daniel M. Silver

Daniel M. Silver (#4758)

cc: Counsel of record (via CM/ECF and electronic mail)